Session

IBD (Posters)

BI 695501 DEMONSTRATES SIMILAR EFFICACY AND COMPARABLE SAFETY TO ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH ACTIVE CROHN'S DISEASE: FINAL ANALYSIS OF THE PHASE III VOLTAIRE-CD STUDY
BI 695501 DEMONSTRATES SIMILAR EFFICACY AND COMPARABLE SAFETY TO ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH ACTIVE CROHN'S DISEASE: FINAL ANALYSIS OF THE PHASE III VOLTAIRE-CD STUDY

IBD (Posters)  et al.

NATURAL HISTORY OF RECURRENT CROHN'S DISEASE FOLLOWING ILEOCOLONIC RESECTION: A MULTICENTER RETROSPECTIVE CROSS-SECTIONAL COHORT STUDY
NATURAL HISTORY OF RECURRENT CROHN'S DISEASE FOLLOWING ILEOCOLONIC RESECTION: A MULTICENTER RETROSPECTIVE CROSS-SECTIONAL COHORT STUDY

IBD (Posters)  et al.

COMPARISON OF THE EFFECTIVENESS AND SAFETY OF THE VEDOLIZUMAB THERAPY USING IN COMBINATION WITH OR WITHOUT CYCLOSPORINE IN ULCERATIVE COLITIS
COMPARISON OF THE EFFECTIVENESS AND SAFETY OF THE VEDOLIZUMAB THERAPY USING IN COMBINATION WITH OR WITHOUT CYCLOSPORINE IN ULCERATIVE COLITIS

IBD (Posters)  et al.

ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH SIGNIFICANTLY IMPROVED INFLAMMATORY BOWEL DISEASE RELATED QUALITY OF LIFE IN A PHASE 2 TRIAL OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS
ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH SIGNIFICANTLY IMPROVED INFLAMMATORY BOWEL DISEASE RELATED QUALITY OF LIFE IN A PHASE 2 TRIAL OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS

IBD (Posters)  et al.

JANUS KINASE SELECTIVITY AND THE IMPACT ON CYTOKINE SIGNALING INHIBITION AT CLINICAL RHEUMATOID ARTHRITIS DOSES
JANUS KINASE SELECTIVITY AND THE IMPACT ON CYTOKINE SIGNALING INHIBITION AT CLINICAL RHEUMATOID ARTHRITIS DOSES

IBD (Posters)  et al.

LONG TERM USE OF BIOLOGIC AND IMMUNOMODULATORS IN INFLAMMATORY BOWEL DISEASE (IBD) AND THE RISK OF DEVELOPING CANCER: A RETROSPECTIVE REVIEW FROM A GENERAL HOSPITAL IN UNITED KINGDOM
LONG TERM USE OF BIOLOGIC AND IMMUNOMODULATORS IN INFLAMMATORY BOWEL DISEASE (IBD) AND THE RISK OF DEVELOPING CANCER: A RETROSPECTIVE REVIEW FROM A GENERAL HOSPITAL IN UNITED KINGDOM

IBD (Posters)  et al.

FREQUENCY AND EFFECTIVENESS OF EMPIRICAL ANTI-TNF DOSE INTENSIFICATION IN INFLAMMATORY BOWEL DISEASE: SYSTEMATIC REVIEW WITH META-ANALYSIS
FREQUENCY AND EFFECTIVENESS OF EMPIRICAL ANTI-TNF DOSE INTENSIFICATION IN INFLAMMATORY BOWEL DISEASE: SYSTEMATIC REVIEW WITH META-ANALYSIS

IBD (Posters)  et al.

TRANSLATIONAL BIOMARKERS FOR SELECTIVE, ORAL, SMALL MOLECULE ?4?7 INHIBITOR MORF-057
TRANSLATIONAL BIOMARKERS FOR SELECTIVE, ORAL, SMALL MOLECULE ?4?7 INHIBITOR MORF-057

IBD (Posters)  et al.

BIOPSIES FROM ULCER EDGE YIELD HIGHER HISTOLOGICAL ACTIVITY SCORES THAN BIOPSIES NEXT TO ULCER IN ACTIVE ULCERATIVE COLITIS
BIOPSIES FROM ULCER EDGE YIELD HIGHER HISTOLOGICAL ACTIVITY SCORES THAN BIOPSIES NEXT TO ULCER IN ACTIVE ULCERATIVE COLITIS

IBD (Posters)  et al.

EFFECT OF 52 WEEKS OF MIRIKIZUMAB ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
EFFECT OF 52 WEEKS OF MIRIKIZUMAB ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

IBD (Posters)  et al.

COMPARATIVE EVALUATION OF TREATMENT PERSISTENCE AND DOSE INTENSIFICATION IN PATIENTS WITH CROHN'S DISEASE TREATED WITH USTEKINUMAB VERSUS VEDOLIZUMAB
COMPARATIVE EVALUATION OF TREATMENT PERSISTENCE AND DOSE INTENSIFICATION IN PATIENTS WITH CROHN'S DISEASE TREATED WITH USTEKINUMAB VERSUS VEDOLIZUMAB

IBD (Posters)  et al.

PRE-BIOLOGIC SCREENING IN A HIGH-RISK AREA: ARE WE ADHERING TO GUIDELINES?
PRE-BIOLOGIC SCREENING IN A HIGH-RISK AREA: ARE WE ADHERING TO GUIDELINES?

IBD (Posters)  et al.

GB004 EXHIBITS PROTECTIVE EFFECTS DIRECTLY ON EPITHELIAL CELLS USING EX VIVO ORGANOID AND MONOLAYER CULTURES
GB004 EXHIBITS PROTECTIVE EFFECTS DIRECTLY ON EPITHELIAL CELLS USING EX VIVO ORGANOID AND MONOLAYER CULTURES

IBD (Posters)  et al.

UCEIS IS ASSOCIATED WITH PRO2, PARTIAL MAYO AND SCCAI REMISSION IN UC: PRELIMINARY RESULTS FORM A PROSPECTIVE STUDY
UCEIS IS ASSOCIATED WITH PRO2, PARTIAL MAYO AND SCCAI REMISSION IN UC: PRELIMINARY RESULTS FORM A PROSPECTIVE STUDY

IBD (Posters)  et al.

PATIENT REPORTED OUTCOMES, PARTIAL MAYO SCORE AND SCCAI ARE EQUALLY ACCURATE IN PREDICTING MUCOSAL HEALING IN UC: PRELIMINARY RESULTS FORM A PROSPECTIVE STUDY
PATIENT REPORTED OUTCOMES, PARTIAL MAYO SCORE AND SCCAI ARE EQUALLY ACCURATE IN PREDICTING MUCOSAL HEALING IN UC: PRELIMINARY RESULTS FORM A PROSPECTIVE STUDY

IBD (Posters)  et al.

INTRAVENOUS USTEKINUMAB REINDUCTION IS EFFECTIVE IN PRIOR BIOLOGIC REFRACTORY PATIENTS WITH CROHN'S DISEASE ALREADY ON 4 WEEKLY DOSING: A REAL-WORLD CASE SERIES
INTRAVENOUS USTEKINUMAB REINDUCTION IS EFFECTIVE IN PRIOR BIOLOGIC REFRACTORY PATIENTS WITH CROHN'S DISEASE ALREADY ON 4 WEEKLY DOSING: A REAL-WORLD CASE SERIES

IBD (Posters)  et al.

DSS COLITIS IS WORSENED AND PROLONGED IN GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR KNOCK OUT MICE COMPARED TO WILD TYPE MICE
DSS COLITIS IS WORSENED AND PROLONGED IN GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR KNOCK OUT MICE COMPARED TO WILD TYPE MICE

IBD (Posters)  et al.

COGNITIVE BEHAVIORAL MINDFULNESS INTERVENTION WITH QUOTIDIAN HOME PRACTICE FOR CROHN'S DISEASE PATIENTS: EFFECT ON PHYSICAL AND MENTAL FUNCTIONING, AND DISEASE-COPING STRATEGIES
COGNITIVE BEHAVIORAL MINDFULNESS INTERVENTION WITH QUOTIDIAN HOME PRACTICE FOR CROHN'S DISEASE PATIENTS: EFFECT ON PHYSICAL AND MENTAL FUNCTIONING, AND DISEASE-COPING STRATEGIES

IBD (Posters)  et al.

DO PSEUDOPOLYPS INCREASE FECAL CALPROTECTIN IN PATIENTS WITH ULCERATIVE COLITIS IN CLINICAL AND ENDOSCOPIC REMISSION?
DO PSEUDOPOLYPS INCREASE FECAL CALPROTECTIN IN PATIENTS WITH ULCERATIVE COLITIS IN CLINICAL AND ENDOSCOPIC REMISSION?

IBD (Posters)  et al.

BIOMARKERS OF ELASTIN DEGRADATION DIFFERENTIATE BETWEEN CLINICALLY INACTIVE AND ACTIVE DISEASE IN UC PATIENTS
BIOMARKERS OF ELASTIN DEGRADATION DIFFERENTIATE BETWEEN CLINICALLY INACTIVE AND ACTIVE DISEASE IN UC PATIENTS

IBD (Posters)  et al.

Item 61 - 80 / 279
1 2 3
4
5 6 7 8 9 10 11 12 13 14